# US 2024/0366816 A1 · Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for Cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0366816 A1
- Document ID: US20240366816A1
- Status: Published application
- Kind: A1
- Application number: 18/771,562
- Filed: 2024-07-12
- Published: 2024-11-07
- Earliest claimed: 2020-01-29
- Assignees: University of Iowa Research Foundation
- Applicants: University of Iowa Research Foundation
- Inventors: Dongyoul Lee; Michael K. Schultz; Mengshi Li; Nicholas Baumhover; F. Christopher Pigge
- Web page: https://patentgrep.com/patent/US20240366816A1

## CPC

- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61K 51/083: {the peptide being octreotide or a somatostatin-receptor-binding peptide}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/1036: {against hormone receptors}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I: T-L-X wherein T is a SSTR2 targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.

## Claims

### Claim 1

A compound having the Formula I:
T-L-X; Formula I,
wherein T is a somatostatin receptor subtype 2 (SSTR2) targeting ligand with the following structure:
wherein the wavy line “” indicates covalent attachment to a chelator or a linker;
wherein L is a linker, wherein the linker is a polyethylene glycol (PEGn), and wherein n=0-10; and wherein X is a chelator with the following structure:
wherein the wavy line “” indicates covalent attachment to a linker or an SSTR2 targeting ligand.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the chelator is optionally chelated with a radionuclide.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the radionuclide is 203Pb or 212Pb.

### Claim 4 (depends on 1)

The compound of claim 1, wherein n=0.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the chelator is optionally chelated with a radionuclide.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the radionuclide is 203Pb or 212Pb.

### Claim 7 (depends on 1)

The compound of claim 1, wherein n=2.

### Claim 8 (depends on 7)

The compound of claim 7, wherein the chelator is optionally chelated with a radionuclide.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the radionuclide is 203Pb or 212Pb.

### Claim 10 (depends on 1)

The compound of claim 1, wherein n=4.

### Claim 11 (depends on 10)

The compound of claim 10, wherein the chelator is optionally chelated with a radionuclide.

### Claim 12 (depends on 11)

The compound of claim 11, wherein the radionuclide is 203Pb or 212Pb.

### Claim 13 (depends on 1)

The compound of claim 1 having a structure selected from the group consisting of:

### Claim 14 (depends on 13)

The compound of claim 13, wherein the chelator is optionally chelated with a radionuclide.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the radionuclide is 203Pb or 212Pb.
